

15-References

- 1- Kanddice L.Kingge. The role of H.pylori in gastrointestinal disease: A guide to identification and eradication 2001; postgrad Med, 110(3): 10-5.
- 2- Williams MP, Pounder RE. H.pylori from benign to the malignant. 1999; Gastroenteral 94 (11 suppl): S11-6.
- 3- Cave Dr. Transmission and epidemiology of H.pylori. 1996; Am J Med 100 (5A): 12-8s.
- 4- Graham Dy, Rakel RE, Fendrick AM. Scope and consequences of peptic ulcer disease: How important is asymptomatic H.pylori infection 2. 1999; postgrad Med 105(3): 100-10.
- 5- Barbara Young, John W.H eath et al. Wheater's functional histology. 2004; 249-285.
- 6- Alan Stevens, James S.Lowe. Human histology. 1997; 190-226.
- 7- Bizzozero, G. Über die schlauch formigen drüsen des Magendarmkanals und die Beziehungen ihres epithets zu dem oberflächenepithel der schleimhaut 1893; Arch. Für. Mikr. Anat. 42: 82-125.
- 8- Salmon, H. Über das spirillum des saugtierrmagens und sein verhalten zu den belegzellen. 1896. Zentrbl fürbakteriol. 19 (Abstract 1) 433-443. Quoted in: Axon, A.T.R. (1988): *Campylobacter pylori* in recent advances in Gastroenterology, Ray pounder (eds). Great Britain, PP. 225-44.
- 9- Kasai, K. and Kobayashi, R. The stomach spirochaete accruing in mammals. 1919. Journal of parasitology, 6:1-10. Quoted in: Axon, A.T.R. (1988): *Campylobacter pylori* in recent advances in Gastroenterolgy. Ray pounder (ed), Churchill Livingstone. Great Britain, PP. 225-44.
- 10- Doenges, J.L. spirochaetes in gastric glands of macacus rhesus and humans without definite history of related disease proceeding of the society of medicine and Biology. 1938, 36:536-538. Quoted in: Axon, A.T.R. (1980): *Campylobacter pylori*. In Recent advances in Gastroenterology Ray pounder (ed.). Churchill Livingstone, Great Britain, PP. 225-44.
- 11- Freedbery, A.S. and Barron, L.T. The presence of spirochaetes in human gastric mucosa 1940; American Journal of digestive diseases, 7: 993-5. Quoted in: Axon, A.I.R. (1980): *campylobacter pylori*. In recent advances in Gastroenterology, Ray pounder. Churchill Livingstone, Great Britain, PP. 225-44.
- 12- Raws, E.A.J. and Tytgat, G.N.G. *Campylobacter pylori*. 1984; W.C. den Ouden, Gist-Brocadis (ed.). Am. Sterdam.

- 13- Palmer, E.D. Investigation of the gastric mucosa spirochaetes of the human. 1954; Gastroenterology, 27: 218-20. Quoted in: Raws, E.A.J. and Tygat. G.N.J (1989): Campylobacter pylori. Brocades (ed.). Amsterdam.
- 14- Steer, H.W. and Collin – Jones, D.G. Mucosal changes in gastric ulceration and their response to carbenoxolone sodium 1975; Gut, 16: 590-7.
- 15- Warren, J.R. and Marshall, B.J. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. 1983; Lancet, 1273-5.
- 16- Maddocks, A.C. Helicobacter pylori (formerly campylobacter pyloridis (pylori). 1990. J. Clin. Pathol; 43: 353-6.
- 17- Mcnutly, C.A.M. and Watson, D.M. Spiral bacteria of the gastric antrum. 1984; Lancet, 1:1068-69.
- 18- Marshall, B.J. and Waren, J.R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. 1984; Lancet, 1:1311-1314.
- 19- Marshall, B.J.; and Goodwin, C.S. Revised nomenclature of compybacter pyloridis. 1987; Int. J. Syst. Bacteriol, 37:68.
- 20- Goodwin, C.S., MC. Culloch, R.K., and Armstrong, J.A., et al. Unusual Cellular fatty acids and distinctive ultrastructure in a new spiral bacterium from the human gastric mucosa. 1989; J. Med. Microbiol 19:257-267.
- 21- Heatley, R.V.; and Wyatt J.I. Gastritis and duodenitis. In: Bockus Gastroenterology Vol. 1 5th edition. By Haubrich WS, Schaffnen F. and Berk JE. WB Saunders Co., Philadelphig London, Toronto, Montreal, Sydney, Tokyo; 1995; P. 633-55.
- 22- Marshall BJ; Francis GJ, and Uttey PG. pyloric campylobacter serology 1984; Lancet 11:281.
- 23- Robert M., Longan, L.H pylori epidemiology 2001; BMJ. 331-5.
- 24- Blaser MJ. Epidemiology and pathophysiology of campylobacter pylori infections. Reviews of infections diseases. 1987; 12, 99-102.
- 25- Parsonaet J, Fridman GD; et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325:1127-31.
- 26- Rokkas. T., Pursey C, and Uzoechina E. Campylobacter pylori and non-ulcer dyspepsia, 1987; AM. J. Gastroenterol., 82:1149-52.
- 27- Celik J. et al. Gastromtestinal path (2nd) edition, 1998; 7: 237.

- 28- Jerris R.C H pylori In: manual of clinical microbiology. By Murray P.R, Baron E. J.P, Tenover F.C, Tenover K.C. 1995; American society of microbiology. Washington DC, 6th edition, P. 492-498.
- 29- Sipponen P. et al. H. pylori among children; 1997.
- 30- Megraud F. Advantages and disadvantages of current diagnostic tests for the detection of H.pylori. Scand J Gastroenterol suppl 1999; 215: 57-62.
- 31- Vaira D. Hotton J., and Cairns SR. Antibody titres to H. pylori after treatment for gastritis. 1988; Br. Med. J. 297:397.
- 32- Zaki H.N. Study of the incidence of specific human IgG against helicobacter pylori among medical personnel. 1992; MSC thesis (internal medicine), Alexandria University.
- 33- Malaty H.M. and Graham D.Y. Importance of childhood socio economic status on the current prevalence of H. pylori infection 1994; Gut, 35: 472-745.
- 34- Kelly, S.M., Patcher, M.C. I., and Farmery, S.M, et al. Isolation of Helicobacter pylori from feces of patients with dyspepsia in the UK. 1994; Gastroenterology, 107: 1671-1674.
- 35- Kjarden S., Fuksa M., and Anderson J. et al. Examination of human stomach biopsies, saliva and dental plaque for A. pylori. 1989; J. Clin. Microbiol, 27: 1397-8.
- 36- Vincent. P, Gottrand. F, and Pernes P. et al. High prevalence of H.pylori infection in cohabiting children epidemiology of a cluster, with special emphasis on molecular typing. 1994; Gut; 35: 313-316.
- 37- Langenberg, M.L., Tytgat G.N., and Schipper, M.t.: et al. Campylobacter – like organism in the stomach of patients and healthy individuals. 1984; Lancet, I: 1348.
- 38- Raus and tytgat G.N.J. Campylobacter pylori: In Wt den. 1989; Quiden Gist Brocadis (eds.) Amsterdam, 25-44.
- 39- Noach, L.A., Rolf, T.M., and Tytgat GN. Electron microscopic study of association between Helicobacter pylori and gastric and duodenal mucosa. 1994; Clin pathol., 7: 699-704.
- 40- Jones, D.M., Lessells A.M, and Eldridgel. Campylobacter like organism on the gastric mucosa culture, histological and serological studies. 1984; Journal of clinical pathology, 37: 1002-6(1984).
- 41- Chan, W.Y, Hui, P.K., and Leung, K.M., et al. Coccoid forms of H.pylori in the human stomach. 1994; AM J. Clin pathol., 102: 503-507.

- 42- Macnoh, R.M, and Airawa S.I. Bacterial motility and the bacterial flagellar motor. 1984);
Annu Rev. Biophys Bioeny. 13: 3183.
- 43- Goodwin CS, Blincow E, Warren TR. Evaluation of cultural techniques for isolating
campylobacter pyloridis from endoscopic biopsies of gastric mucosa. 1985; J. Clin.
Pathol, 138: 1127-1131.
- 44- Caselli, M., Aleotti, A.; and Boldrini, P.; et al Ultrastructural patterns of Helicobacter
pylori. 1993; Gut; 34: 1507-1509.
- 45- Taylor DE, Hargreaves JA. Isolation and characterization of campylobacter pyloridis
from gastric biopsies. Am. J. Clin. Path. 1987; 87: 49-54.
- 46- Jones, D.M; Eldridge, J.; Fox, A.J; Sethi, P. and Whorwell, P.J. Antibody to the gastric
campylobacter – like organisms, clinical correlations and distribution in the normal
population 1986; J.Med. Microbiol., 22: 57-62.
- 47- Tytgat, G.N. Compylobacter pylori. Past, present and future 1989. ADIS Press. (eds)
Spain.
- 48- Buck, G.E. and Smith, J.S. Medium supplementation for growth of campylobacter
pyloridis. 1987; J.Clin. Microbiol. 25: 597-9.
- 49- Goodwin, C.S., Armstrong, J.A., and Marshall, B.J. Campylobacter pyloridis, gastritis
and peptic ulceration. 1986; J.Clin. Pathol., 39:353-6.
- 50- Dooley, C.P. and Cohen, H. The clinical significance of campylobacter pylori. 1988;
Ann. Int. Med., 108: 70-9.
- 51- Kung, J.S.; HO, B. and Chain, S.H. Biotyping of Campylobacter pylori. 1989; J.Med.
Microbial., 29: 203-6.
- 52- Itah, T.; Yanagawa, Y., and Shingaki, M. Isolation of Campylobacter-like organisms from
human gastric mucosa and characterization of isolates. 1987; Microbial. Immunol., 31(7):
603-14.
- 53- Tompkins, D.S. and West, A.P. Campylobacter pylori, acid and bile. 1987; Journal of
Clinical pathology, 40: 1387.
- 54- Ribeiro, C.D. and Gray, S.J. Long term freeze storage of Campylobacter pyloridis. 1987;
J.Clin Pathol., 40: 1265.
- 55- Lam S.K., Hui W.M. and Ching CK. H.pylori infection peptic ulcer disease, part 1
(epidemiology, Pathogenesis and etiology)

- 56- Crabtree J.E., Taylor J.D.; Wyatt, J.I. Mucosal recognition of H.pylori. 1994; Lancet; 338: 332-5.
- 57- Hazell S.L., Lee A, Rrady, L. H.pylori and gastritis. 1991; Lancet, ii 15-17.
- 58- Seroiseik J, Slomiang A, and Slominay BL. Evidence for weakening gastric integrity by H.pylori; 1995. Gastroenterol, 23:585.
- 59- Herris, A.W., Gummett P.H., Baron, J.H. Eradication of H.pylori. 1996; Gut; 38: 663-7.
- 60- Hirai M., Azume J. Ito S., Kato T., Kohli Y., and Fujiki N. High prevalence of neutralizing activity to H.pylori cytotoxine in serum of gastric carcinoma patients. 1994; Int. J. Cancer. , 56.
- 61- Mass F, Calam, J.J. Effect of eradication of H.pylori in acid secretion. 1993; Gut; 34:888-92.
- 62- Pounder R.E. H.pylori and Gastroduodenal secretory function. 1996; Gastroenterology. 110(3): 947-9.
- 63- Jone, C.; Calm, M., et al. Helicobacter pylori collaborative group. 2001; B.M. J., 21: 517-69.
- 64- Moss. S, Calan J. Acid secretion and sensitivity gastric in gastric cancer patients. 1990; Gut 34: 888-892.
- 65- Moss SF., Legon S.L. and Calam, J. Cytokine gene expression in H.pylori associated antral gastritis.1994; Gut., 35: 1567-1570.
- 66- Marshall B.J; Barrett LJ; et al. Urea protects H.pylori but not campylobacter jejuni from the bactericidal effect of acid. 1990; Gastroenterol 98: 106:109.
- 67- Evans D.G., et al. pathology of H.pylori in gastric mucosa; 1988. Clin. Path.
- 68- Lingwoord C.A., et al. Isolation and characterization of compyobacter pyloridis from gastric from gastric biopsies. 1989; Microbiol.
- 69- Smoot D.T. et al., pathophysiology of compylobacter pyloridis 1989; 58:67.
- 70- Lehninger A.L., et al. Biochemist 1978; 71: 480-84.
- 71- Levi, S. Et al., Helicobacter and changes in the mucosa of GIT. Biochemist Med. 1989; 32-39.
- 72- Slomiany B.L. et al. Enzymatic effect of Helicobacter pyloridis angastric mucosa; 1989.
- 73- Cave D.R. et al. Effect of compylobacter pylori on gastric mucosal secretions; 1989; 112: A70.

- 74- Craig P.M. et al. Epidemiology and pathophysiology of *compylobacter pylori* infections 1989; Vol. 12, 99-102.
- 75- Engstrand L. et al. Effects of *helicobacter pyloridis* gastritis on gastric secretion in healthy human being. 1989; *Am J physiol.* (76) Karnes W.E. et al. inflammatory reaction of *compylobacter pylori*. 1990; 339: 1920-30.
- 76- Karnes W.E. et al. Inflammatory reactions of *compylobacter pylori* 1990; 339: 1920-30.
- 77- Caramel, R.; Perez, G.; and Blaser, M.J.; *Helicobacter pylori* infection and food. Cabalamin malabsorption. 1994; *Digestive diseases and sciences*, 309-314.
- 78- Taylor, D.N.; and Blaser M.J. the epidemiology of *Helicobacter pylori* infection 1991; *Epidemiologic Review*, 13:42-59.
- 79- Fiedorek, S.C.; Casteel, H.B, and pumphrey C.I, et al. The role of *Helicobacter pylori* in recurrent. Functional abdominal pain in children *Am.* 1992; *J. Gastroentero*; 87: 347-49.
- 80- Blaser, M.J. Hypothesis on the pathogenesis and natural history of *Helicobacter pylori* – induced inflammation 1992; *Gastroenterology*, 102: 20-727.
- 81- Fan, X.G., Chau, A., and Fa, X.J. et al,. Increase gastric production of interleukin-8 and tumour necrosis factor in patients with *Helicobacter pylori* infection 1995; *J.Clin pathol.*, 48: 133-136.
- 82- Karttunen, R.; Rarttunen and Erke, H.T.; et al. Interferon gamma and interleukin 4 secreting cells in the gastric antrum in *H.pylori* positive and negative gastritis. 1995; *Gut.*, 36:341-345.
- 83- Suzuki, M.; Miuras, and Mori, M; et al. Rebampide, a norel antiulcer agent, attenuates *Helicobacter pylori* induced gastric mucosal cell injury associated with neutrophil derived oxidant. 1994; *Gut.*, 35: 1375-1378.
- 84- Dekigai, H., Murakami, M., and kitat. Mechanism of *Helicobacter pylori* associated gastric mucosal injury 1995; *Digestive diseases and science*, 40: 1332-1339.
- 85- Norgaard, A., Pendersen, L.P., and Nielsen, H. Neutrophil degranulation by *Helicobacter pylori* proteins. 1995; *Gut.*, 36: 354-57.
- 86- Slomiany, B.L., Murty. V., Piotrow, ski. J., Liau, Y.H. et al. Glycosulfatase activity of *Helicobacter pylori* toward gastric mucin. 1992; *Biochem Biophys Res commun.*; 183: 506-13.
- 87- Markesich, D.C., Annd, B.S., and Lew G.M., et al. *Helicobacter pylori* infection does not reduce the viscosity of human gastric mucus gel. 1995; *Gut.*, 36:327-329.

- 88- Buck, G.E.; Gourley, W.K. and Lee, W.K. Relation of campylobacter pyloridis to gastritis and peptic ulcer 1986; J. Inf. Dis., 153(4): 664-69.
- 89- Hazell, S.L., Lee A. and Brady, L. Campylobacter pyloridis and gastritis: Association with intracellular spaces and adaptation to an environment of mucus as important factors in colonization of the gastric epithelium. 1986; J. Inf. Dis., 153:63.
- 90- Hazell, S.L. and Lee A. campylobacter pyloridis, urease, hydrogen back diffusion and gastric ulcers. 1986; Lancet, ii: 15-17.
- 91- Brady, C.E.; Hadfield, T.L. and Hyatt, J.R. Acid secretion and serum gastrin levels in individuals with campylobacter pylori 1988; Gastroenterology 94:923.
- 92- Marshall, B.J., Barret, L.J., Parkash, C. McCallum, R.W. and current R. Urea protects Helicobacter pylori from the bactericidal effect of acid. 1990; Gastroenterology, 99: 697-702.
- 93- Goodwin, C.S., Armstrong. J.A. and Chilwars, T. Transfer of campylobacter pyloridis and C. mustelae to Helicobacter gen. Nov. as Helicobacter pylori comb. Nov. and Helicobacter mustelae comb. Nov. Respectively Int. J. systematic 1989; Bacterial 39: 2378-2379.
- 94- Mclean, R.J.C., Cheng, K.J., Goold, W.D. and Costertan, J.W. Cytochemical localization of urease in a rumen staphylococcus sp. By electron microscopy App. Env. Microbiol. 1985; 49: 253-255.
- 95- Giannella, R.A, Broitman, S.A., and Zamcheck, N. Gastric acid barrier to ingested micro-organisms in man. Studies in vivo and in vitro. 1972; Gut, 13:251-256.
- 96- Marchall, B.J, Armstrong, J.A., McGeachie, D.B. and Glancy, R.J. Compylobacter infection and gastroduodenal disease 1985; Med. J. Australia, 142: 439-444.
- 97- Morris, A. and Nicholson, r. Ingestion of campylobacter pyloridis causes gastritis and raised fasting gastric pH. 1987; Am. J. Gastroenterol., 82:192-199.
- 98- McCarthy, C., Mrcpi, Patchett S., et al. Long Term prospective study of Helicobacter pylori in non-ulcer dyspepsia. 1995; Digestive diseases and sciences, 40: 114-119.
- 99- Bernerson B, Johnson R., Bostrodl, L., Stramme. B., Sommer AI, and Burhoil P.G. Is H.pylori the cause of dyspepsia? 1992; BMJ; 304:1276.
- 100- Talley NJ. A relationship between H.pylori and non-ulcer dysepepsia is there enough data to know? 1994; Eur. J. Gastroenterol. Hepatol., 6:567.
- 101- Lambert JR, Borneo M. and Korman MG. H.pylori and non-ulcer dyspepsia, randomized controlled trial. 1989; Gastroenterology; 96:284.

- 102- Yang JY., Tay H.M, and Wee A. effect of colloidal bismuth subcitrate on NUD. 1990; Gut; 31:476.
- 103- Shalaby, SI. Causal relationship of H.pylori to gastroduodenal lesions. MD thesis 1993; Tropical medicine, Faculty of Medicine – Minia University.
- 104- Marshall BJ, Armstrong JA, and Mc-Gechis. Attempt to fulfill koch postules for pyloric campylobacter 1995; Med. J., 142:436.
- 105- Schubert, T.T.; Schubert A.B, and Mack. Symptoms, gastritis and Helicobacter pylori in patients referred for endoscopy 1992; Gastrointest. Endosc., 38: 357-360.
- 106- Moagyedi P. and Axon AJ. H.pylori by biopsy ureas test. 1995; Oxford Blackwell scientific publication P.58.
- 107- Shallcross TM., Rathbone BJ., and Heatly RV. H.pylori and non-ulcer dyspepsia. In: H.pylori and gastroduodenal diseases. 1992; Oxford, Blackwell scientific publication; 165.
- 108- Hill I.D., Sinclair, Smith C., and Lastovical AJ. Transient protein losing enteropathy associated with acute gastritis and campylobacter pylori. 1987; Arch. Dis. Child.; 62:1215.
- 109- Collen M.J, Johnson D.A. et al. Gastric acid hypersecretion in patients with gastroesophageal reflux disease 1990; Gastroenterology; 98: 654-661.
- 110- Hazell S.I, Carrick J., Lee A. helicobacter pylori can infect the oesophagus when gastric tissue is present 1998; Gastroenterology; 94:A179.
- 111- Taley N.J, and Phillips S.F. Non ulcer dyspepsia: potential causes and pathophysiology 1988; Ann. Intern. Med; 108:865-879.
- 112- Mccallum R.W, De Luca V., Marshall B.J. et al. Prevalence of compylobacter like organisms in patients with gastroesophageal reflux disease Vs normals. 1987; Gastroenterology; 92: 1524.
- 113- Cheng E.H, Bermanski P., Silver, Smith M., et al prevalence of campylobacter pylori in oesphagitis, gastritis, and duodenal disease 1989; Arch. Intern. Med; 149:1373.
- 114- Agnholf. J., Allinberg J. Moller-peterson J. et al. The occurence of Helicobacter pylori in the oesophagus 1991; Eur.J. Gastroenterol., 3:685-688.
- 115- Rosiora. C, Marks, Micheals et al. Esophagitis and Helicobacter pylori in children: incidence and therapeutic implications 1993; Am. J. Gastroenteral. 88(4): 510-513.

- 116- O'Connor HJ. Review article *Helicobacter pylori* and gastro oesophageal reflux disease-clinical implications and management. 1999; *Aliment pharmacol* 13:117-27.
- 117- Lee J.M., O'moran C.A et al. Impact of *H. Pylori* infection on gastroesophageal reflux 1998; *Gastroenterology*. 114: A200.
- 118- Labenz J; Malfertheiner P. *Helicobacter pylori* in gastro-oesophageal reflux disease: causal agent, independent or protective factor? 1997; *Gut*. 41:279-80.
- 119- Shioani A., Nishioka S. *Helicobacter pylori* and symptomatic relapse of gastro-oesophageal reflux disease: a randomized controlled trial. 1999; 357:1738-42.
- 120- Kuipers E.J. et al. *Helicobacter pylori* augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. 1996; *Gastroenterology* 110:725-732.
- 121- Labenz J. and Borch G. Highly significant change of the clinical course of relapsing and complicated peptic ulcer disease after cure of *H. pylori* infection 1994; *Am. J. Gastroenterol.*; 89, 1785.
- 122- O'Donnel M, Alexander Williams J, Healthley Rev et al. Management issues for debate: The problems in perspective 1993; *Aliment pharmacool ther* 7 (suppl2) 4925.
- 123- Goodwin CS. Duodenal ulcer, campylobacter and the leaking roof concept. 1988; *Lancet* 11, 1467-1469.
- 124- Wyatt J.I, Rathbone BJ, Sobola SM et al. Gastric epithelium in the duodenum, its association with *H. Pylori* and inflammation 1990; *J. Clin pathol* 43:986
- 125- Bewett EJ, Smith JTL, Nwokolo CU, Hudson M, sawyer AM, pounder RE. Eradication of *H.pylori* abolishes 24h hypergastrinemia. 1991; a prospective study.
- 126- Mai, Peterzperez GI, Whal LM, Washl SM, Mlaser MJ, Smith PD. Inflammatory and cytoprotective responses by human monocytes are induced by *H. pylori*: possible role in the pathogenesis of type B gastritis. 1991; *Gastroenterology* 98: A662.
- 127- Soll AH. Pathogenesis of peptic ulcer and implications for therapy. 1990; *New Engl J. Med* 322: 909-916.
- 128- Tytgat GNJ, Axon ATR, Dixon MF et al. *H.pylori* causal agent in peptic ulcer disease in working party report of the world congress of Gastroenterology. 1990; sydney. Austrilia Oxford, Blackweel PP 363:45.
- 129- Labenz, Barsh G. Evidence for the essential role of *H.pylori* in gastric ulcer disease. 1994; *Gut*: 35:1922.

- 130- Chan W.Y, Hui P.K, Cheungpsy et al. Benign gastric ulcer associated with H.pylori 1990; Journal of gastroenterology and Hepatology; 19:47.
- 131- Chan W.Y, Hu, P.K, J. K.C et al. Epithelial damage by Helicobacter pylori in gastric ulcers 1991. Histopathology; 19:47.
- 132- Marshall B.J. Virulence and pathogenicity of H.pylori. 1991; journal of Gastroenterology Hepatology, 6:121.
- 133- Graham DY, Lew GM, Malaty HM et al. Factors influencing the eradication of H.pylori with triple therapy. 1992; Gastroenterol 102:498-496.
- 134- Parkin DM., Muics, Whelam SL., Gao YT., Farlay J., Powell J. Cancer incidence in five continents. 1995; International Agency for research on cancer. France; 6:30 1-53.
- 135- Ricci V, Ciacci C, Zenrilli R, Simmi P, Tummer MKR, Blanco CD., Bruni CB, Cover TL, Blaser MJ., and Roman M. Effect of H. pylori on gastric epithelial cell migration and proliferation in vitro; Role of vac A and Cag A. 1996; Inf. Imm; 64(7): 28-29.
- 136- Wink A. de, Boer Guido N.J., Tygat. Treatment of H.pylori infection: B.M.J. 2001, 320:31-34.
- 137- Lynch D.A., Mapstone NP., Clark AV., Sobala GM, Jackson P, Morrison, L., Dixon MF., Quirk P., and Axon AT. Cell proliferation in H.pylori associated gastritis and the effect of eradication therapy. 1995; Gut, 36:346.
- 138- Correa et al., H.pylori and gastric carcinogenesis 1995; Am. J. Surg. (19): 37-43.
- 139- IARC. Working group on the evaluation of carcinogenic risk to humans, Schistosomes, liver flukes and H.pylori infection with H.pylori. 1994; Vol. 61. Lyon, France: international agency for research on cancer; 177-240.
- 140- James M., Schemian M.D., Alan F. et al. H.pylori and Gastric cancer. 1999; Am. J. Med; 106:222-226.
- 141- Parsonnet J, Hansen S, Radriguez, Warnke RA, Jelhum E. and Friedman GD. H.pylori infection and gastric lymphoma. 1994; N.Engl. J.Med; 330:126-7.
- 142- Wothers poon AC, Ortis Hidalogoc, Falzon Mr, Isaacson PG. Helicobacter pylori associated gastritis and primary B cell gastric lymphoma. 1991; Lancet 338:1175-1176.
- 143- Hussel, Isoocson PG, Crabtree JE, Spencer J., The response of cell form low grade B cell gastric lymphomas of mucosa associated lymphoid tissue to H.plori 1993; Lancet 342:571-574.

- 144- Bayerdoorffer E, Neubauer, Rudolph B et al. Regression of primary gastric lymphoma of mucosa associated lymphoid tissue type after cure of H.pylori infection 1992; Lancet 345: 1591-1594.
- 145- Yon WC, Blotwj, Lijy et al. Precancerous gastric lesions in population at high risk of stomach cancer. 1993; cancer Res., 53: 1317-1321.
- 146- Supponen P, Seppala K, Gastric carcinoma: Failed adaptation of H.pylori scan. J. 1992. Gastroenterol 193 (supp): 33-38.
- 147- Blast MJ Hypothesis on the pathogenesis and natural history fo H.pylori induced inflammation 1992; Gastroenterol 102:720-727.
- 148- Taylor P.R., Mason R.C, Filipe M.I. et al. Gastric carcinogenesis int eh rat induced by duodenogastric reflux without carcinogens. 1991; Gut, 32: 14-47.
- 149- Scheiman M, James M., Alan F., Cutler et al. H.pylori and gastric cancer. 1999; (106): 222-226.
- 150- Abdel-Wahab, M. Attallah AM, Elshal MF, Zalate KR. Ibrahim NM., Ezzat F. Correlation between endoscopy, histopathology and DNA flow cytometry in patients with gastric dyspepsia. 1997; Hepatogastroenterol 43: 1313-1320.
- 151- C.J. van der Woude, J.H. Kleibeuker, P.L.M. Jansen, H.Moshage. chronic inflammation, Apoptosis and (pre) malignant lesions in the GIT, 2004; 6: 123-130.
- 152- James Rhodri Bebb, Lopa leach, Abed Zaitaun, Neil Hand, Darren letley, Rachael Thomes and John C Atherton. The effect of H.pylori on the cadherin-catenin complex. May 2006; 10:1136.
- 153- Lydia E. Wroblewski, P.J.M. Noble, Adeliria Pagliocca, D.Mark Pritchard, C.Antomy Hart, Fiona Campbell, Andrew R. Dodson, Graham J. Dockray and Andrea Varro. Stimulation of MMP-7 by H.pylori in human gastric epithelial cells: role in epithelial cell migration. Journal of cell science 116, 3017-3026; 2003.
- 154- J Pathbol. Malgun (clear) cell change in H.pylori gastritis reflects epithelial genomic damae and repair. American journal of pathology 2003; 162: 1203-1211.
- 155- International agency for research on Cancer, World Health Organization. Infection with H.Pylori. In: Schistosomes, liver flukes and H.pylori. Lyon: IARC Monogr Eval Carcing Risks HUM 1994; 60: 177-240.
- 156- Meucci G, Tatarella M, Vecchi M., Ranzi ML, Biguzzi E, Beccari G, Clerici E, de franchis R.High prevalence of H.pylori infection in patients with colonic adenomas and carcinomas. J Clin Gastro enteral. 1997; 25:605-7.

- 157- Fireman Z, trost L, Kopelman Y, Segal A, Sternberg A. Helicobacter pylori: seroprevalence and colorectal cancer. IS, Med Assoc. J. 2000; 2:6-9.
- 158- Breuer-Katschinski B, Nemes K, Marr A, Rump B, Leiendecker B, Breuer N, Goebell H. Helicobacter pylori and risk of colonic adenomas. Colorectal adenoima Group. Digestion 1999; 60:210-5.
- 159- Parsonnet J. Bacterial infection as a cause of cancer. Environ Health perspect 1995, 103 suppl 8:263-8.
- 160- Natalia Zumkeller. Helicobacter pylori and risk of colorectal carcinomas: Case-control study under consideration of potential pathomechamisms. Dr. Med, 2006.
- 161- Johnson L.R. Regulation of gastrointestinal growth. In: Johnson LR, editor. Physiology of gastcointestinal tract. Volume 1, 2 nd edition New York: Raven, Pa 87: 301-3.
- 162- Kussyk CJ, McNeil No, Johson LR. Stimulation of growth of a colon cancer cell line by gastrin. Am J physical 1986; 251: G597-G601.
- 163- Karlin DA, McBath K, Jones RD, et al. Hypergastrinemia and colorectal carcinogens in the rat. Cancer Lett 1985; 29:73-8.
- 164- McGregor DB, Jones RD, Karlin DA, Ronsdahl MM. Trophic effects of gastrin on colorectal neoplasma in the rat. Ann Surg 1982; 995: 219-23.
- 165- Beauchap RD, Townsend CM, singh P, et al. Proglumide, a gastrin receptor antagonist; inhibits growth colon cancer and enhances survival in mice, Ann surg 1985; 202: 303-9.
- 166- Hoosein NM, Klener PA, Curry RC, et al. Anti proliferative effects of gastrin receptor antagoniots and antibodies to gastrin on human colon carcinoma cell lines. Cancer Res 1988; 48: 7179-83.
- 167- Hoosein NM, Kiener PA, Curry RC, Brattain MG. Evidence for autocrine growth stimulation of cultures of colon tunour cells by a gastrin / cholecstokinin – like peptide cell Res 1990; 186: 15-21.
- 168- Watson SA, Durrant LQ, Wencyk PM, et al. Intracellular gastrin in human gastrointestinal tumour cells. J NATl cancer Inst 1991; 34: 171-4.
- 169- Smith JP, Wood JG, Soloman TE, elevated gastrin levels in patients with colon cancer or adenomatous polyps. Dig Dis Sci 1989; 49: 488-92.
- 170- UPP JR, Singh p, Townsend CM, Thompson JC, clinical significance of gastrin receptors in human colon cancer. Cancers Res 1989; 49:488-92

- 171- Bundred NJ, Whit field BCS, Stanton E, et al. Gastric surgery and the subsequent risk of colorectal cancer. *Br J surg* 1985, 77:618-9.
- 172- Stemmermann GN, Nomura AMY, Chyou pH. Cancer incidence following subtotal gastrectomy. *Gastroentology* 1991; 101: 711-5.
- 173- Talley NJ, Chute C.G, Larson DE, et al. Risk for colorectal adenocarcinoma in pernicious anemia. *Ann Intern Med* 1989; 111: 738-72.
- 174- Brinton LA, Kune S, Watson LF, et al. peptic ulcer surgery and colorectal cancer risk (letter). *Br J Surg* 1988; 75:187.
- 175- Kune GA, Kune S, Watson LF, et al. Peptic Ulcer surgery and colorectal cancer risk (letter). *Br j surg.* 1988; 75:187.
- 176- Charnley RM, Thomas WM, Stanely J, Morris DC. Serum gastrin concentrations are elevated in colorectal cancer. *Br J surg.* 1989; 76:1346.
- 177- Charnley RM Thomas WM, Stanley J, Morris DC. Serum gastrin concentrations in colorectal cancer patients. *Ann R Coll surg Engl* 1992; 74: 138-41.
- 178- Seitz JF. Elevated gastrin levels in patients with colorectal cancer (Letter). *J. Clin Gastro enterol* 1989; 11:362.
- 179- Seitz JF, Grovinni M, Monger G, et al. La gastrinémie dans les cancers colorectaux. *Gastroentrol Clin Biol* 1992; 16: 385-7.
- 180- Wong K, Bearashall K, Waters CM, et al. postprandial hypergastrinemia in patients with colorectal cancer. *Gut* 1991; 32: 1352-4.
- 181- Kikendall JW, Glass AR, Sobin LH, Bowen PE. Serum gastrin is not higher in subjects with colonic neoplasia. *AM J. Gastroentrol* 1992; 87: 1394-7.
- 182- Suzuki H, Matsumoto K, Terashima H. Serum levels of gastrin in patients with colorectal neoplasia. *Dis colon Rectum* 1988; 31: 716-7.
- 183- Yapp R, Modlin IM, Kumar RR, et al. Gastrin and colorectal cancer: evidence against an association *Dig. Dis Sci* 1992; 37: 482-4.
- 184- Artur Hartwich, Stanislaw. J. Konturek, Piotr Pierzchalisk Monika Zuchowicz, Piotr C. Konturek, Wladyslaw Bielansk: Krzysztaf Marlicz, tereson starzynska, Malgorzata Lawniczar Molecular basis of colorectal cancer-role of gastrin and cyclo oxygen ase-2. *Med Sci Monit*, 2001; 7(6): 1171-1181.
- 185- Grawford JM: The gastrointestinal tract. In Robbins pathologic basis of disease. Cotran RS, Kumar VK, Collins T WB Saunders Co, Philadelphia. 1999; 75-843.

- 186- Mueller-Decker K, Albert C, Iukanov T: cellular localization of cyclooxygenase isoenzymes in Crohn's disease and colorectal cancer. *Int J colorectal Dis*, 1999; 14: 212-228.
- 187- Williams CS, Mann M, Du Bois RN: The role of cyclooxygenases in inflammation, cancer and development. *Oncogene* 1999; 18 (55): 7908-7916.
- 188- Dimberg J, Samuelsson A, Hugander A: differential expression of cyclooxygenase 2 in human colorectal cancer. *Gut*, 1999; 45(5): 730-732.
- 189- Tifan OC, Smith RM, Thompson BD: Overexpression of cyclooxygenase induces cell cycle arrest. Evidence for a prostaglandin independent. *J Biol Med*, 1999; 274(48): 34141-34147.
- 190- Hawk E, Lubet R, Limburg P: Chemoprevention in hereditary Colorectal cancer syndromes. *Cancer*, 1999; 86 (8 suppl): 1731-1743.
- 191- Dannenberg AJ, Zakin D: Chemoprevention of colorectal cancer through inhibition of cyclooxygenase-2. *Semin Oncol*, 1999; 26(5): 499-504.
- 192- Sheehan KM, Sheehan K, O'Donoghue DP: The relationship between cyclooxygenase-2 expression and colorectal cancer. *JAMA*, 1999; 282(13): 1254-1257.
- 193- Giovannucci E: The prevention of colorectal cancer by aspirin use *Biomed pharmacother*, 1999; 53: 303-308.
- 194- Sakuma K, Fujimori T, Hirabayashi K: Non-steroidal anti inflammatory drugs and cyclooxygenase-2 selectivity in gastroenterology *Rev Esp Enferm Dig*, 1999; 91: 305-309.
- 195- Johnson LR, Aures D, Yenl: pentagastrin induced stimulation of the in vitro incorporation of 14 C-leucine into protein of the gastrointestinal tract. *AMJ physiol*, 1969; 217: 251-254.
- 196- Sobhani I, Lehy T, Laurent-puig P; chronic endogenous hypergastrinemia in humans: evidence for amitogenic effect on the colonic mucosa. *Gastroenterology*, 1993; 15: 22-30.
- 197- Danesh J: Helicobacter pylori infection and gastric cancer: systemic review of the epidemiological studies. *Aliment pharmacol Ther*, 1999; 13: 851-856.
- 198- Konturek PC, Bielanski W, Bobrzynski A: Gastric mucosal expression and luminal release of growth factors in gastric carcinoma and duodenal ulcer patients before and after eradication of Helicobacter pylori. *J physiol pharmacol*, 1997; 48: 375-382.

- 199- Konturek SJ, Kontusek PC, Hartwich A: Helicobacter pylori infection and gastrin and cyclooxygenase expression in gastric and colorectal malignancies. Reg Pep, 2000; 93: 13-19.
- 200- Smith Am, Watson SA: Review article: Gastrin and colorectal cancer. Aliment pharmacol Ther, 2000; 14: 1231-1247.
- 201- Bielanski W, Kontusek SJ: New approach to 13C urea breath test: capsule-based modification with low-dosed of 13C-urea breath test in the dog diagnostic of Helicobacter pylori infection. J physical pharmacol, 1997; 47: 545-553.
- 202- Konturek PC, Pierzchalski P, Konturek SG: Helicobacter pylori induced apoptosis in gastric mucosa through an upregulation of Bax expression in humans. Scand J Gastroenterol, 1999; 34:375-383
- 203- Bruer-Katschinski P, konturek SJ: Helicobacter pylori induced apoptosis in gastric mucosa through an up regulation of Bax expression in humans. Scand J. Gastroentrol, 1999; 34:375-383.
- 204- Konturek JW, Bielanski W, Konturek SJ: Eradication of Helicobacter pylori and gastrin – sonatostatin link in duodenal ulcer patients. J physiol pharmacol, 1996; 47: 161-176.
- 205- Bliss PW, Healey ZV, Arebi N et al: NC-methyl histamine and histamine stimulate gastrin release from rabbit G-cells via histamine H2-receptors. Aliment pharmacol Ther, 1999; 13: 1669-1674.
- 206- Konturek PC, Konturek SJ, Sito E et al: luminal Methyl histamine stimulates gastric acid secretion in duodenal ulcer patients via releasing gastrin. Eur J pharmacol, 2001; 42: 181-185.
- 207- Thorburn CM, Friedum GD, Dickinson CJ: Gastrin and colorectal cancer: a prospective study. Gastroentrolgy, 1998; 115: 275-280.
- 208- Konturek PC, Bielanski W, Konturek SJ: Helicobacter pylori associated gastric pathology. J physiol pharmacol 1999; 50:695-710.
- 209- Kokkolaa, Rautelin H, puolakkainen P: Diagnosis of Helicobacter pylori infection in patients with atrophic gastritis: comparison of histology, 13C-urea breath test, and serology. Scand J Gastroentrol, 2000; 35:138-141.
- 210- Kinzler Kw, Vogelstein B: lessons from hereditary colorectal cancer cell, 1996; 7: 159-170.
- 211- Webb PM, Forman D: Helicobacter pylori as a risk factor for cancer. Balliere is Clin Gastroentrols 1995; 9: 563-582.

- 212- Blaser MJ, Perez-Perez GZ, Kleanthous H: Infection with *Helicobacter pylori* strains possessing cag A associated with an increased risk of developing adenocarcinoma of the stomach. *Cancer Res*, 1995; 55: 2111-2115.
- 213- Konturek PC, Konturek SJ, Bielanski W: Role of gastrin in gastric cancerogenesis in *Helicobacter pylori* infected humans. *J physiol pharmacol*, 1999; 50: 857-873.
- 214- Baldwin GS, Zhang QZ: Measurement of gastrin and transforming growth factor. *Cancer Res*, 1992; 52:2261-2267.
- 215- Finley GG, Koski RA, Melbom MF et al: Expression of gastrin gene in the normal human colon and colorectal carcinoma. *Cancer Res*, 1993; 53:2919-2926.
- 216- Xuz, Dai B, Dhruva B, Singh P: Gastrin gene expression in human colon cancer cells measured by a simple competitive PCR method. *Life Sci*, 1994; 54:671-678.
- 217- Singh P, Owlia A, Varro A, et al: Gastrin gene expression is required for the proliferation and tumorigenicity of human colon cancer cells. *Cancer Res*, 1996; 56: 4111-4115.
- 218- Hartwich As, Konturek SJ, P: ierzchalski P et al: *Helicobacter pylori* infection, cyclooxygenase and apoptosis in colorectal cancer. *Internat J colorectal Dis*, 2001.
- 219- Vansaling WW, Nielson FC, Friis-Hansen et al: Expression but incomplete maturation of progastrin in colorectal cancer. *Gastroenterology*, 1993; 104:1099-1107.
- 220- Raderer M, Pfeffel F, Pohl G: Regression of colonic low grade B cell lymphoma of the mucosa associated lymphoid tissue type after eradication of *H. pylori* Gut, 2000; 46(1): 133-135.
- 221- Lipsky PE: Role of cyclooxygenase-1 and -2 in health and disease *AM J orthop*, 1999; 28 (suppl 1): 8-12.
- 222- Uefuji K, Ichikura T, Mochizuki H: cyclooxygenase-2 expression is related to prostaglandin biosynthesis in human gastric cancer. *Clin Cancer Res*, 2000; 6(1): 135-138.
- 223- Abdulrahmans. Al-Mulhim, FRCSI, Fics; Hamdoun Al Hosieny Mohammad, MD: Hypergastrinemia and *H. pylori* infection as a risk factor for colorectal cancer, *Annals of Saudi Medicine* Vol 22, NOS 3-4, 2002.
- 224- Thoreson, A-C. T., Borre, M.B., Anderson, P. & 6 other authors, (1995). Development of PCR-based technique for detection of *Helicobacter Pylori*. *FEMS Immunol Med microbial* 10, 325-334.

- 225- Blom, K, Svennerholm, A-M. Bohlin, I (2002). The expression of the H. pylori genes urea A and nap is higher in vivo than in vitro measured by quantitative competitive reverse transcriptase-P CR. FEMS Immunol Med Microbiol 32, 219-226.
- 226- Niclas Grahn, Mounira Hmani-Aifa, Karin Fransen, peter Soderkvist and Hans-Jurg Monstein: Molecular Identification of Helicobacter DNA present in human colorectal adenocarcinomas by 16 sr DNA PCR amplification and pyrosequencing analysis, journal of medical Microbiology (2005), 54, 103
- 227- Konturek, P.C., Kania, J., Kontwek, J.W., Nikiforwk, A., Konturek, S. J & Hahn, E.G. (2003). H. pylori infection, atrophic gastritis, cytokines, gastrin, COX=2, PPAR and impaired apoptosis in gastric carcinogenesis Med Sci Moint 9, SR65-SR78.
- 228- Sartor, R.B. 1995. Current concepts of the eitiology and pathogenesis of ulcerative colitis and Crohn's disease. Gaslroentrol. Clin. N. Am. 24: 475-507.
- 229- Farrel, R.J., and J. T. La Mont. 2002, Microbial factors in inflammatory bowel disease. Gastroenterol. Clin. N.Am. 31:41-62.
- 230- Cahill, R.J., C.J. Foltz, J.G. Fox, C.A. Dangler, F. Powrie, and D.B. Schauer. 1997. - Inflammatory bowel disease: an immune mediated condition triggered by bacterial infection -with Helicobacter hepaticus. Infect Immun. 65:3126-3133.
- 231- Faltz, C.J., J.G. Fox, R.J. Cahill, R.C. Murphy, L. Yan, B. Shames, and D.B. Shauer. 1998. Spontaneous inflammatory bovel disease in multiple mutant mouse lines: association with colonization by Helicobacter hepaticus. Helicobacter 3: 69-78.
- 232- Kullberg M.C., J.M. Ward, P.L. Gorelick, P. Casper, S. Hieny, A. Cheever, D. Jankovic, and A. Sher. 1998. Helicobacter hepaticus triggers colitis in specific – pathogen - free interleukin – 10(16-1) – Infect. Immun. 66:5157-5166.
- 233- Shomer, N.H., C.A. Dangler, M.D. Schrenzel, and J.G. Fox. 1997 Helicobacter billis induced inflammatory bowel disease in scid mice with defined flora. Infect. Immun. 65: 4858-4864.
- 234- Saunders K.C., Z. Shen, F.E. Dewhirst, B.J. Paster, C.A. Daugler, and J.G. Fox. 1999. Novel intestinal Helicobacter species isolated from coltontop tanarins (saguinus Oedipus) with chronic colitis' J. Clin. Microbiol. 37: 146-151.
- 235- Fox, J.G., L. Handt, S. Xu, Z. Shen F.E. Dewhirst, B.J. Paster, C.A. Dangler, K. Lodge, Motzel, and H. Klein. 2001. Novel Helicobacter species isolated from rhesus mmkeys with chronic idiopathic colitis. J. Med. Microbiol. 50: 421-429.

- 236- Adriana Goncalves Oliveira, Maria das Gracas Pimenta sanna, Gifone Aguiar Rocha, Andreia Maria Camargos Rocha, Adriana santos, Renato Dani, Frederic passos Marinho, Liano sia Moreim maria de Lourdes Abreu Ferrari, Silvia Beleza Moura, Lucia porto fonseca Castro, D.M Queuroz: *Helicobacter* species in the intestinal mucosa of patients with ulcerative colitis, *journal of clinical microbiology*, Jan, 2004, P. 384-380.
- 237- AE Duggon, I Usmani, KR Neal and RF A Logan: Appendicectomy, childhood hygiene, *Helicobacter pylori* status, and risk of inflammatory bowel disease: *Gut*, 1998; 43; 4494-498.
- 238- El-Omar E, penman I, Cruikshank G, et al. Low prevalence of *Helicobacter pylori* in inflammatory bowel disease: association with sulphasalazine. *Gut* 1994; 36: 1384-8.
- 239- Halme L, Rautelin H, Leidenius M, et al. Inverse correlation between *Helicobacter pylori* infection and inflammatory bowel disease. *Clin pathol* 1996; 49: 65-7.
- 240- Sobala GM, Crabtree JE, Dixon MF et al: Clinical features, local and systematic immune response. Gastric mucosal histology, and gastric juice ascorbic acid concentrations. *Gut*, 1991; 32: 1415-1418.
- 241- Robert JR, Sachar DB, Greenstein AJ: Severe gastrointestinal hemorrhage in Crohn's disease. *Ann Surg*, 1991; 213:207.
- 242- Meining A, Bayerdorffer E, Bastlein E et al: Focal inflammatory infiltrations in gstric biopsy specimens are suggestive of crohn's diseese. Crohn's disease study group, German. *Scand j Gastroenteral*, 1997; 32(8): 813-8.
- 243- Herz R, Schaube J, Meining A, Stolate M: Gastritis associated crohn's disease can be masked by *Helicobacter pylori* gastritis. *Scand J Gastroenteral*, 1999; 34(5): 471-3.
- 244- Del prente G: The concept of type I and type II helper T cells and their cytokines a humans. *Intern Rev Immunol*, 1998; 16; 427-455.
- 245- D Elios MM. Manghetti M, Almerigogna F et al: Different cytokine profile and antigen – specificity repertoire in *Helicobacter pylori* specific T cell clones from the antrum of chronic gastritis patients with or without peptic ulcer. *Euro J Immunol*, 1997; 27: 1715-1755.
- 246- Haur AC, Finn TM, MacDonald TT et al: Th 1 and Th2 cytokine production in low grade B cell gastric MALT-type lymphomas stimulated in vitro with H pylori. *J Clin pathol*, 1997; 50: 957-960.

- 247- Bamford KB, Fanx, Crowe SE et al: Lymphocytes in the human gastric mucosa during *Helicobacter pylori* have T helper cell 1 phenotype. *Gastroenterology*, 1998; 114: 482-492.
- 248- Oberhuber G, Puspok A, Oesterreicher C et al: Focally enhanced gastritis: a frequent type of gastritis in patients with Crohn's disease *Gastroenterology*, 1997; 112(3): 698-706.
- 249- Ivan r, Jovanovic, Tomica N. Milosavljevic, Goran P. Jankovic, Marfan M. Micev, predrag D. Dugalic, Dfordj'je saranovic, Milenko M. Ugljesic, Dragan V. popovic, Mirko M. Bulajic: Clinical onset of crohn's disease after eradiction therapy of *Helicobacter pylori* infecton. Does *Helicobacter pylori* infection interact with natural history of inflammatory bovel diseases?. *Med Sci Monit*, 2001; 7(1): 137-141.
- 250- Hurtley MG, Hudson MJ, Swarbrick et al: The rectal mucosa – associated microflora in patients with ulcerative colitis. *J Med Microbiol*, 1992; 36:96-104.
- 251- Bennet JD, brinkman M: Treatment of ulcerative colitis by implantation of normal colonic -flora. *Lancet*, 1989; 1:164.
- 252- Wagtmans MJ, Witte AM, Taylor DR et al: Low seroprevalence of H pylori antibodies in historical sera of patients with Crohn's disease. *Scand J Gastroenterol*, 1997; 32(7): 712-8.
- 253- Parente F, Molteni P, Bollani S et al: prevalence of H pylori infection and related upper GIT lesions in patients with inflammatory bowel diseases. A cross – sectional study with matching scand J *Gastroenterol*, 1997; 32(11): 114-6.
- 254- Meining A, Bayeradrffer E, Bastlein E et al: Focal inflammatory infiltrations in gastric biopsy specimens are suggestive of Crohn's disease. Crohn's Disease study group, Germany. *Scand J Gastroenterol*, 1997; 32(8): 813-8.
- 255- Halme L, Kakkainen P, Routelin H et al: High frequency of *Helicobacter* negative gastritis in patients with Crohn's disease. *Gut*, 1996; 38(3): 379-83.
- 256- Kolho KL, Rautelin H, Lindahi H, Savilahti E: *Helicobacter pylori* – positive gastritis in pediatric patients with chronic inflammatory bowel disease. *J pediater Gastroenlerol Nutr*, 1998; 27(3): 292-5.
- 257- Ruuska T, Vaajalahti P, Arajarvi P, Maki M: prospective evaluation of upper gastrointestinal mucosal lesions in children with ulcerative colitis and crohn's disease. *J pediater Gastroenterol Nutr*, 1994; 19(2): 181-6.

- 258- Asa Ljungh, MD, PhD and Torkel Wadstrom, MD, PhD: The role of microorganisms in biliary tract disease. *Current Gastroenterology Reports* 2002, 4: 167-171.
- 259- Sorin T. Barbu. Cluj – Napoca, Romania M.Orlowski and Co-workers(Gdansk Poland): *Gastro – Conference Berlin 2005*, 14: 1-16.
- 260- Nilsson H.O, Taneera, Castedal M, Glatz E, Olsson R, Wadstrom T. Identification of *Helicobacter pylori* and other *Helicobacter* species by PCR, hybridization and partial DNA sequencing in human liver samples from patients with primary sclerosing cholangitis or primary biliary cirrhosis. *J Clin. Microbiol.* 2000; 38: 1072-1076.
- 261- Nilsson H-O, Mulchandani r, Tranberg K-G, Stenram U, Wadstrom T. *Helicobacter* SP identified in human livers from patients with cholangio – and hepatocellular carcinoma. *Gastroenterol* 2001; 120: 323-324.
- 262- Avenaud P, Marais A, Monteiro L, Le Bail B, Bioulac sae P, Balabaud C, Megraud F. Detection of *Helicobacter* species in the liver of patients with and without primary liver carcinoma cancer 2000; 89: 1431-1439.
- 263- De Magalhaes Queriroz DM, Santos A. Isolation of a *Helicobacter* strain from the human liver. *Gastroenteral.* 2001; 121: 1023-1024.
- 264- Wadstrom T, Ljungh A, Willen R. primary biliary cirrhosis and primary sclerosing cholangitis are of infection origin! *Gut* 2001; 49:454.
- 265- Ananieva O, Nilsson I, Vorobjova T, Uibo R, Wadstrom T. Immune response to bile-tolerant *Helicobacter* species in patients with chronic liver diseases, a randomized population group, and healthy blood donors. *Clin. Diagn. Lab. Immunol.* 2002; 9: 1160-1164.
- 266- Nilsson I, Kornilov' ska I, Lindgren S, Ljungh A, Wadstrom T. Increased prevalence of seropositivity for non-gastric *Helicobacter* species in patients with autoimmune liver disease. *J. Med. Microbiol.* 2003; 52: 848-853.
- 267- Apostolov E, Abu Al Soud W, Nilsson I, Kornilovska I. Usenko V, Lyzogubov V, Gaydar Y, Wadstrain T, Ljungh A. *Helicobacter pylori* and other *Helicobacter* species in gall bladder and liver of patients with chronic cholecystitis detected by immunological and molecular methods. *Scand. J. Gastroenterol.* 2005; 40: 96-102.
- 268- Fox JG, Dewhirst FE, Shen Z, Feng Y, Taylor NS, pasteur BJ, Ericson RL, Lau CN, Correa P, Araya JC, and Roa1. Hepatic *helicobacter* species identified in bile and gallbladder tissue from Chileans with chronic cholecystitis. *Gastroenterology* 114: 755-763, 1998.

- 269- Leong RW and Sung J.J. Review article: Helicobacter species and hepatobiliary diseases. *Aliment pharmacol Ther* 16: 1037-1045, 2002.
- 270- Arlin B. Rogers and James G. Fox. Inflammation and cancer I. Rodent models of infections, gastrointestinal and liver cancer. *Am J physiol Gastrointest liver physiol* 286: 361-366, 2004.
- 271- Fox JG, Schauer DB, Wadstrain T. Enterohepatic helicobacter spp. (*curr opin Gastroenterol* 2001; 17: 528-31.
- 272- Sung JJY, Go Myy. Reversible Kupffer cell suppression in biliary obstruction is caused by hydrophobic bile acids. *J Hepatol* 1999; 30: 413-8.
- 273- 273- Xin Wang, Roger Willen, Marie Svensson, ASA Lfungh and Torkel Wadstrom. Two year follow-up of Helicobacter pylori infection in C 57 BL/6 and Balb/CA mice; *APMB* 111: 514-22, 2003.
- 274- Mairi Macarthur, Georgina L. Hold, and Emad M. Elomar. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastro intestinal malignancy; *Am J physiol Gastrointest liver physiol* 286: G515-G520, 2004.
- 275- Yanai AY, Hirata Y, Mitsuno S, Maeda S, Shibata W, Akanuma M, Yoshida H, Kawabe T, and Ometa M. Helicobacter pylori induces antiapoptosis through nuclear factor-kB activation. *J infect Dis* 188: 1741-1751, 2003.
- 276- Gupta RA, Polk DB, Krishna U, Israel DA, Yan F, DuBois RN, and peek RM Jr. Activation of peroxisome proliferators activated receptor gamma suppresses nuclear factor kB-mediated apoptosis induced by Helicobacter pylori in gastric epithelial cells. *J Biol Chem* 276: 31059-31066, 2001.
- 277- Sutton P, Kolesnikow T, Danon S, Wilson J, and Lee A. Dominant nonresponsiveness to Helicobacter pylori infection is associated with production of interleukin 10 but not gamma interferon. *Infect Immun* 68: 4802-4804, 2000.
- 278- Tsujii M and DuBois RN. Alteration's in cellular adhesion and apoptosis in epithelial cells over expressing prostaglandin endoperoxide synthase 2. *cell* 83: 493-501, 1995.
- 279- Barbera – Guillem E, Nyhus JK, Wolford CC, Friece LR, and Sampsel JW. Vascular endothelial growth factor secretion by tumour – infiltrating macrophages essentially supports tumour angiogenesis, and IgG immune complexes potentiate the process. *Cancer Res* 62: 7042-7049, 2002.
- 280- Dalglish AG and O'Byrne KJ. Chronic immune activation and inflammation in the pathogenesis of AIDS and cancer. *Adv cancer Res* 84: 231-276, 2002.

- 281- Liu XH, Kirschenbaum A, LuM, YaoS, Dosoretz A, Holland JF, and Levine AC. Prostaglandin E2 induces hypoxia – inducible factor-1 stabilization and nuclear localization in a human prostate cancer cell line. J Biol chem. 277: 50081-5086, 2002.
- 282- is essential for myeloid cell-mediated inflammation. Cell 112: 645-657, 2003.αCramer T, Yamanishi Y, Clausen BE, Forster I, Pawlinski R, Mackman N, Haase VH, jaenisch R, Corrm, Nizet V, Firestein GS, Gerber HP, Ferrara N, and Johnson RS. HIF-1
- 283- Luperchio SA and Schauer DB. Molecular pathogenesis of citrobacter rodentium and transmissible murine colonic hyperplasia. Microbes Infect 3: 333-340, 2001.
- 284- Zaitoun, A. M. Histology compared with chemical testing for urease for rapid detection of Helicobacter pylori in gastric biopsy specimens. J. Clin. Pathol., 46: 684-685 (1993).
- 285- Cutler AF; Havstad S; et al. Accuracy of invasive and non invasive tests to diagnose Helicobacter pylori infection. Gastroenterology 1995; 109: 136-41.
- 286- James S; and Everett D. Diagnosis of campylobacter pylori infections. The "Gold standard and the alternatives 1990.
- 287- Rathbone B.J. et al, H. pylori and gastroduodenal disease Oxford (1986).
- 288- Gray et al staing & H. pylori organism 1986.
- 289- Rawles, J.W; Harris, M.L: and Paull G.; et al; antibody to campylobacter pyloridis in endoscopy personnel, patients and control. Gastroenterology, 92: 1589. (1986).
- 290- Rocha, G.A.; Queiroz D.M, and Mendezen et al. simple carbolfuchsin staining for showing C.pylori and other spiral bacteria in gastric mucosa, J. Cli. Pathol., 42: 1004-5 (1989).
- 291- Loffeld, R.J.F.; Stobbering E.; Flendring J.A.; et al.; Helicobacter pylori in gastric biopsy specimens. Comparison of culture modified Giemsa stain and Immuno histochemistry. A retrospective study. Journal of pathology, Vol. 165: 69-73 (1991).
- 292- Trallero, E.P.; Montes M.; and Al corta M.; et al.; Non endoscopic methodto obtain Helicobacter pylori for culture. Lancet, 345: 622-23. (1995).
- 293- McNutly, C.A.M. Detection of Helicobacter pylori by the biopsy urease testlin: Helicobacter pylori and gastroduodenal disease. Oxford. Blackwell scientific publications, P.58 (1992).
- 294- Blaser, M.J. Campylobacter pylori in gastritis and peptic ulcer disease. Tgak4-Shoin Medical publishers, Inc. New York, Tokyo; (1989).

- 295- Neithercut W.D.; Maline A.; and Chitt Ajalu Rs, et al. Detection of *Helicobacter pylori* infection of the gastric mucosa by measurement of gastric aspirate ammonium and urea concentrations, *Gut.*, 32; 973-976 (1991).
- 296- El-Zaatari F.A.K; Ngugn A.M.H.; and Genta RM et al; Determination of *Helicobacter pylori* status by reverse transcription polymerase chain reaction comparison with urea breath test. *Digestive Diseases and Sciences*, 40: 109-113 (1995).
- 297- Hammar, M.; Tyszkiewicz, T.; and Wadstrom T. ; et al. Rapid detection of *Helicobacter pylori* in gastric biopsy material by polymerase chain reaction *J. Clin. Microbial.*, 30:54:58 (1992).
- 298- Monstein, H.J., Nikpour. Badr, S. & Jonasson, J. (2001). Rapid molecular identification and subtyping of *H.pylri* by pyrosequencing of the 165rDNA variable V1 and V3 regions. *FEMS microbial*.
- 299- Atherton, J. C.; and Spiller R.C.; The urea breath test for *Helicobater pylori*. *Gut.*, 35: 723-25 (1994).
- 300- Graham Dy; Lew GM; Klein P; et al. Factors influencing the eradication of *Helicobacter* with tripple therapy. *Gastroenterology* (1992); 102: 493-6.
- 301- Marshall BJ; and Surveyor I. Carbon 14 urea breath test for the diagnosis of campylobacter pylori associated gastritis. *J. Nucl. Med.* 1988; 29: 6-11.
- 302- Wu, J.C.; Liu, G.L; and Zhang Z.H.; et al. 15 NH₄ excretion test: A new method for detection of *H.pylori* infection. *J. Clin Microbial*. 130: 181-184 (1992).
- 303- Jones, D.M.; Lessells A.M.; and Eldridgel. Campylobacter like organism on the gastric mucosa culture, historlogical and serological studies. *Journal of clinical pathology*, 37: 1002-6 (1984).
- 304- Von Wulffen, H.; Heesemann J.; and Butzow G.H.; et al. Detection of cambylobacter pyloridis in patients with antrum gastritis and peptic ulcers by culture, complement fixation test, and immunoblot, *J. Clin Microbial.*, 24; 716-20. (1986).
- 305- Dent, J.C.; McNutly, C.A.M.; and UFF JS et al. Campylobacter pylori urease. A new serological test *Lancet*, 1:1002 (1988).
- 306- Megraud F. Advantages and disadvantages of current diagnostic tests for the detection of *Helicobacter pylori*. *Scand J Gastroenterol suppl.* 1999; 215: 57-62.
- 307- National Institutes of Health consensus development panel on *Helicobacter pylori* in peptic ulcer disease. NIH consensus conference. *JAMA* 1994; 272: 65-9.

- 308- The European *Helicobacter pylori* study Group. Current European concepts in the management of *Helicobacter pylori* infection. The Maastricht consensus report. *Gut* 1997; 41: 8-13.
- 309- Lam SK, Talley NJ. Report of the 1997 Asia pacific consensus conference on the management of *Helicobacter pylori* infection. *J Gastroenterol Hepatol* 1998; 13: 1-12.
- 310- Sung JJ, Lin SR, Ching JY, et al. Effects of curing *Helicobacter pylori* infection on precancerous gastric lesions: one-year follow up of a prospective randomized study in China. *Gastroenterology* 1998; 114: A 296.
- 311- JWu, J Sung. Treatment of *Helicobacter pylori* infection: HKMJ 1999; 5: 145-9.
- 312- Howden CW, Hunt RH. Guidelines for the management of *Helicobacter pylori* infection. Ad Hoc Committee on parameters of the American college of gastroenterology. *AM J Gastroenterol* 1998; 93: 2330-2338.
- 313- Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G, current concepts in the management of *Helicobacter pylori* infection – the Maastricht 2-200 consensus report. *Aliment pharmacol ther* 2002; 16: 167-180.
- 314- Coelho LG, Leo-Barua R, Quigley EM. Latin-American consensus conference on *Helicobacter pylori* infection. Latin-American National Gastroenterological societies affiliated with the Inter-American Association of Gastroenterology (AIGE) *Am. J. Gastroenterol* 2000; 9: 2688-2691
- 315- Ulmer H.J, Beckerling A, Gatz G. Recent use of proton pump inhibitor-based triple therapies for the eradication of *H.pylori*: abroad data review. *Helicobacter* 2003; 8:95-140.
- 316- Buzas G.M, Jozan J. Eradication of *Helicobacter pylori* infection in Europe: a meta-analysis based on Congress abstracts, 1997-2002. *Orv. Hetil* 2004; 145: 2035-2041.
- 317- Vergara M, Vallve M, Gisbert JP, Calvet X. Meta-analysis: Comparative efficacy of different proton-pump inhibitors in triple therapy for *Helicobacter pylori* eradication. *Aliment pharmacol Ther* 2003; 18: 647-654.
- 318- Gisbert JP, Khorrami S, Calvet X, Pajares JM. Systematic review Rabeprazole – based therapies in *Helicobacter pylori* eradication. *Aliment pharmacol Ther* 2003; 17: 751-764.
- 319- Vallve M, Vergara M, Gisbert JP, Calvet X. Single VS. double dose of a proton pump inhibitor in triple therapy for *Helicobacter pylori* eradication: a meta-analysis. *Aliment pharmacol Ther* 2002; 16: 1149-1156.

- 320- Fischbach LA, Van Zanten S, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first line anti-Helicobacter pylori quadruple therapies. *Aliment Pharmacol Ther* 2004; 20: 1071-1082.
- 321- Gene E, Calvet X, Azagra R, Gisbert JP. Triple vs. quadruple therapy for treating H pylori infection: a meta-analysis. *Aliment pharmacol Ther* 2003; 1137-1143.
- 322- Graham DY, Belson G, Abudayyeh S, Osato MS, Dore MP, El Zimaity H.M. Twice daily (mid-day and evening) quadruple therapy for H pylori infection in USA. *Dig Liver Dis* 2004; 36: 384-387.
- 323- Hunt RH, Fallone CA, Thomson AB. Canadian Helicobacter pylori consensus conference update: Infections in adults Canadian Helicobacter Study Group. *Can J Gastroenterol* 1999; 13: 213-217.
- 324- Vakil N, Lanza F, Schwartz H, Barth J. seven-day therapy for Helicobacter pylori in USA. *Aliment pharmacol Ther* 2004; 20: 99-107.
- 325- Calvet X, Garcia N, Lopez T, Gisbert JP, Gene E, Roque M. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxicillin for treating Helicobacter pylori infection. *Aliment Pharmacol Ther* 2000; 14: 603-609.
- 326- De Boer SY, Vol Meeberg PC, Siem H, de Boer WA. Comparison of four-day and seven-day pantoprazole – based quadruple therapy as a routine treatment for H pylori infection. *Neth J Med* 2003; 61: 218-222.
- 327- Lara LF, Ciseros G, Gurney M, Van Ness M, Jarfoura D, Moauro B, Polen A, Rutecki G, Whittier F. One day quadruple therapy compared with 7-day triple therapy for H pylori infection. *Arch Intern Med* 2003; 163: 2079-2084.
- 328- Hojo M, Miwa H, Nagahara A, Sato N. pooled analysis on the efficacy of the second-line treatment regimens for H pylori infection. *Scand J Gastroenterol* 2001; 36: 690-700.
- 329- Bilardi C, Dulbecco P, Zentilin P, Relioni S, Liriano E, Parodi A, Accornero L, Savarino E, Manss C, Mamone M, Vigneri S, Savarino V. A 10-day Levofloxacin – based therapy in patients with resistant H pylori infection: a controlled trial-*Clin Gastroenterol Hepatol* 2004; 2:997-1002.
- 330- Nista EC, Candelli M, Cremonini F, Cazzato IA, Di Caros, Gabrielli M, Santarelli L, Zocco MA, Ojetti V, Carlons E, Cammarota G, Gasbarrini G, Gasbarrini A.

- Levofloxacin – based triple therapy vs. quadruple therapy in second-line H. pylori treatment: a randomized trial. *Aliment pharmacol Ther* 2003; 18: 627-633.
- 331- Perrif, Festa V, Clemente R, Villani MR, Quitadamo M, Caruso N, Bergoli ML, Andriulli A. Randomized study of two "rescue" therapies for H pylori infected patients after failure of standard triple therapies. *AMJ Gastroenterol* 2001; 96: 58-62.
 - 332- Bock H, Koop H, Lehn N, Heep M. Rifabutin-based triple therapy after failure of H pylori eradication treatment: preliminary experience *J Clin Gastroenterol* 2000; 31: 222-225.
 - 333- Roghani HS, Massarrat S, Shirekhoda M, Butorab 2. Effect of different doses of furazolidone with amoxicillin and omeprazole on eradication of H pylori. *J Gastroenterol Hepatol* 2003; 18: 778-782.
 - 334- Isakov V, Domareva I, Koudryaytseva L, Maev I, Genskayaz. Furazolidone – based triple "rescue therapy" vs. quadruple "rescue therapy" for the eradication of H pylori resistant to metronidazole. *Aliment pharmacol Ther* 2002; 16: 1277-1282.
 - 335- Wong WM, Wong BC, Lu H, Gu Q, Yin Y, Wang WH, Fung FM, Lai KC, Xia HH, Xiao SD, Lam SK. One – week omeprazole, Furazolidone and amoxicillin rescue therapy after failure of H pylori eradication with standard triple therapies. *Aliment pharmacol Ther* 2002; 16: 1793-798.
 - 336- Dore MP, Graham DY, Mele R, Marras L, Nieddu S, Manca A, Realdi G. Colloidal bismuth subcitrate – based twice-a-day quadruple therapy as primary or salvage therapy for H pylori infection *AM J Gastroenterol* 2002; 97: 857-860.
 - 337- Gisbert JP, Calvet X, Bujanda L, Marcos S, Gisbert JL, Pajares JM. "Rescue" therapy with rifabutin after multiple H pylori treatment failures. *Helicobacter* 2003; 8: 90-94.
 - 338- Gisbert JP, Castro fernandez M, Bermejo F, Perez-Aisa A, Ducons J, Fernandez – Bermejo M, Bory F, Cosme A, Benito LM, Lopez-Rivas L, Lamas E, Pabon M, Olivares D. Third-line Rescue Therapy with Levofloxacin after two H pylori treatment failures. *AM J Gastroenterol* 2006; 101: 243-247.
 - 339- Zullo A, Vaira D, Vakil N, Hassan C, Gatta L, Ricci C, De Francesco V, Menegatti M, Tampieri A, Perna F, Rinaldi vs Perri F, Papadia C, Formari F, Pilati S, Mete LS, Merla A, Potti R, Marinone G, Savioli A, Compo SM, Faleo D, Lerardi E, Miylioli M, Morini S. High eradication rates of H pylori with a new sequential treatment. *Aliment pharmacol Ther* 2003; 17: 719-726.

- 340- De Francesco V, Zullo A, Margiotta M, Marangi S, Burattini O, Berloco P, Russo F, Barone M, Di Leo A, Minenna MF, Stoppino V, Morini S, panella C, Francavilla A, Lerardi E. sequential treatment for H pylori does not share the risk factors of triple therapy failure. *Aliment pharmacol Ther* 2004; 19: 407-414.
- 341- Francavilla R, Lionetti E, Castellaneta SP, Magista AM, Boscarelli G, piscitelli D, Amoruso A, Di Leo A, Miniello M, Francavilla A, Cavallo L, Lerardi E. Improved efficacy of 10-Day sequential treatment for *Helicobacter pylori* eradication in children: a randomized trial. *Gastroenterology* 2005; 129: 1414-1419.
- 342- Zullo A, Gatta I, De Francexo V, Hassan C, Ricci C, Bemabucci V, Cavina M, Lerardi E, Morini S, Vaira D. High rate of H pylori eradication with sequential therapy in elderly patients with peptic ulcer. A prospective controlled study. *Aliment pharmacol Ther* 2005; 21: 1419-1424.
- 343- Scaccianoc G, Hassan C, Panarese A, Piglionica D, Morini S, Zullo A. H pylori eradication with either 7 day or 10 day triple thera pies, and with a 10 day sequential regimen. *Can J Gastroenteral* 2006; 20: 113-117.
- 344- De Francesco V, Margiotta M, Zullo a, Hassan C, Troiani L, Burattini O, Stella F, Di Leo A, Russo F, Marangi S, Monno R, Stoppino V, Morini S, panella C, Lerardi E. Clarithromycin – resistant genotypes and eradication of H pylori. *Ann Intern Med* 2006; 144: 94-100.
- 345- Gisbert JP, Hermida C, Pjares JM. Are twelve days of omeprazole, amoxicillin and clarithromycin better than six days for treating H. pylori infection in peptic ulcer and in non-ulcer dyspepsia? *Hepatogastroenterology* 2001; 48: 1383-1388.
- 346- Perri F, Festa V, Merla A, Barberani F, Pilotto A, Andriulli A. Randomized study of different second-line therapies for H. pylori infection after failure of the standard 'Mastricht triple therapy'. *Aliment pharmacol Ther* 2003; 18: 815-820.
- 347- Saad R, Schoenfeld P, kim H, Chey WD. Levofloxacin – based triple therapy versus bismuth-based quadruple therapy for persistent H. pylori infection: a meta analysis. *AM J Gastroenterol* 2006; 101: 488-496.
- 348- Best L, Cooper-Lesins G, Haldane D, Veldhyzen Von Zantens. *Helicobacter pylori* antibiotic resistance in Canadian populations. *Gastroenterology* 2004; 124(4) suppl 2: A-189.
- 349- Graham DY, Lew GM, Malaty HM, Evans DG, Evans DJ, Jr., Klein PD, Alpert LC, Genta RM. Factors influencing the eradication of H. pylori with triple therapy. *Gastroenterology* 1992; 102: 493-496.

- 350- Houben MH, Van de Beek D, Hensen EF, Craen AJ, Rauws EA, Tytgat GN. A systemic review of H. pylori eradication therapy-the impact of antimicrobial resistance on eradication rates. *Aliment pharmacol Ther* 1999; 13: 1047-1055.
- 351- Megraud F, Marshall BJ. How to treat H. pylori. First-line, second-line, and future therapies. *Gastroenterol Clin North AM* 2000; 29: 759-773, Vii.
- 352- Vakil N. Are there geographical and regional differences in H. pylori eradication? *Can J Gastroenterol* 2003; 17 suppl B: 30B-32B.
- 353- Broutet N, Tchamgoue S, Pereira E, Lamouliatte H, Salamon R, Megraud F. Risk factors for failure of H. pylori therapy results of an individual data analysis of 2751 patients. *Aliment pharmacol ther* 2003; 17: 99-109.
- 354- Matsuo K, Hamajima N, Ikehara Y, Suzuki T, Nakamura T, Matsuura A, Tajima K, Tominaga S. Smoking and polymorphisms of fucosyltransferase gene Le affect success of H. pylori eradication with lansoprazole, amoxicillin and clarithromycin. *Epidemiol Inf.* 2003; 130: 227-233.
- 355- Vikram Kate, N. Ananthrishon. Treatment of H.pylori infection A review. *Indian Journal of Pharma*; 2001; 33: 410-416.
- 356- Richard J. Saad and William D. Chey. Treatment of Helicobacter pylori infection in 2006. *GI physiology*, University of Michigan Medical Center, Ann Arbor, Michigan, 2006; 30:35.
- 357- Aleksandar Nagorni. Helicobacter pylori at the end of the second milenium. *The scientific journal of FACTA Universitatis*. Vol.7, No. 1, 2000 PP. 15-25.
- 358- Czinn SJ. What is the role for vaccination in H.pylori? *Gastroenterology* 1997; 113: 5144-5153.
- 359- Moran AP. Future outlook in Helicobacter pylori research. In: Moran AP and O'Morain CA -(ED): pathogenesis and host response in H.pylori infections. Normed Verlag GmbH, Bad Homburg, 1997; 242-250.
- 360- Tomb JF, White O, Kerlavage AR, et al. The complete genome sequence of the gastric pathogen H. pylori. *Nature* 1997; 388: 539-547.
- 361- Milosavifevic T. Helicobacter pylori: aboljenja digestivnog sistema. *Arch Gastroentrohepatol* 1998; 17 (suppl. No. 8): 51-510.
- 362- Lee A. Commentary: helicobacter pylori and future research. *Gastroenterology* 1997; 113: 5167-5169.